Home World News FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E... World News FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation By Ogkologos - March 11, 2026 382 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Severe mental illness linked to low attendance at cancer screening May 4, 2023 Some Hormone Therapy Drugs For Breast Cancer Could Reduce Alzheimer’s Risk May 8, 2020 Self-care Isn’t Selfish August 25, 2021 How MRI add-ons could accelerate the development of new treatments May 9, 2023 Load more HOT NEWS Woman Finds Out She Has Breast Cancer From Museum Photo Booth FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC Activity of Alectinib for ALK-Rearranged Metastatic Solid Tumours, Other Than NSCLC How to Plan a ‘Safecation’
